The short version of IGF-1 marker fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
=== Industrial and chemical === Technetium-99 decays almost entirely by beta decay, emitting beta particles with consistent low energies and no accompanying gamma rays. Moreover, its long half-life means that this emission decreases very slowly with time. It can also be extracted to a high chemical and isotopic purity from radioactive waste. For these reasons, it is a U.S. National Institute of Standards and Technology (NIST) standard beta emitter, and is used for equipment calibration. Technetium-99 has also been proposed for optoelectronic devices and nanoscale nuclear batteries. Like rhenium and palladium, technetium can serve as a catalyst. In processes such as the dehydrogenation of isopropyl alcohol, it is a far more effective catalyst than either rhenium or palladium. However, its radioactivity is a major problem in safe catalytic applications. When steel is immersed in water, adding a small concentration (55 ppm) of potassium pertechnetate(VII) to the water protects the steel from corrosion, even if the temperature is raised to 250 °C (523 K). For this reason, pertechnetate has been used as an anodic corrosion inhibitor for steel, although technetium's radioactivity poses problems that limit this application to self-contained systems. While (for example) CrO2−4 can also inhibit corrosion, it requires a concentration ten times as high. In one experiment, a specimen of carbon steel was kept in an aqueous solution of pertechnetate for 20 years and was still uncorroded.
For many years, controversy has surrounded the use of involuntary treatment and use of the term "lack of insight" in describing patients. Internationally, mental health laws vary significantly but in many cases, involuntary psychiatric treatment is permitted when there is deemed to be a significant risk to the patient or others due to the patient's illness. Involuntary treatment refers to treatment that occurs based on a treating physician's recommendations, without requiring consent from the patient. Inpatient psychiatric wards may be secure (for those thought to have a particular risk of violence or self-harm) or unlocked/open. Some wards are mixed-sex whilst same-sex wards are increasingly favored to protect women inpatients. Once in the care of a hospital, people are assessed, monitored, and often given medication and care from a multidisciplinary team, which may include physicians, pharmacists, psychiatric nurse practitioners, psychiatric nurses, clinical psychologists, psychotherapists, psychiatric social workers, occupational therapists and social workers. If a person receiving treatment in a psychiatric hospital is assessed as at particular risk of harming themselves or others, they may be put on constant or intermittent one-to-one supervision and may be put in physical restraints or medicated. People on inpatient wards may be allowed leave for periods of time, either accompanied or on their own. In many developed countries there has been a massive reduction in psychiatric beds since the mid 20th century, with the growth of community care.
As JD Vance and Marco Rubio met the Danish and Greenlandic foreign ministers Lars Løkke Rasmussen and Vivian Motzfeldt, the White House posted a meme on Twitter with the question: "Which way, Greenland man?" with imagery implying a choice between the United States and an ominous-looking China and Russia. Heidi Beirich of the Global Project Against Hate and Extremism described the meme as reflecting a key concept in neo-Nazi and white supremacist subculture, explaining that "Western man is code for white man, and one of the most popular racist books in these subcultures is Which Way Western Man, which has been featured in a Department of Homeland Security post celebrating manifest destiny." Trump has engaged in online trolling, posting an altered image that features the US flag covering Canada, Greenland, and Venezuela and an AI image of himself planting a US flag in Greenland, marked as "US territory" and "EST. 2026." Paul Buvarp, a researcher on disinformation and propaganda at the Norwegian Defence Research Establishment, described Trump's claims about imminent Chinese and Russian threats to Greenland as detached from observable reality and emblematic of information manipulation rather than genuine security analysis. Buvarp argued that the rhetoric functions as propaganda by deliberately creating uncertainty, anxiety, and confusion. On 29 January 2026, German broadcaster Norddeutscher Rundfunk was fined by Greenlandic police after comic artist Maxi Schafroth attempted to raise the US flag near a cultural centre in Nuuk as part of a stunt.
That is how this entire mass of suffering originates.The Mahahatthipadopama-sutta (M 28) contains another short explanation of dependent origination:these five grasping aggregates are indeed dependently originated. The desire, adherence, attraction, and attachment for these five grasping aggregates is the origin of suffering. Giving up and getting rid of desire and greed for these five grasping aggregates is the cessation of suffering.
Sources: en.wikipedia.org
All the proteolytic activity of the asparagine peptide lyases is only self-cleavages, then no further peptidase activity occurs. The main residue of the active site is the asparagine and there are other residues involved in the catalytic mechanism, which are different between the different families of asparagine peptide lyases. The cleavage mechanism consists in the cyclization of the asparagine, assisted by other active site residues. In certain conditions, the asparagine cyclic structure nucleophilically attacks its C-terminal peptide bond to the main chain forming a new bond to create a stable succinimide, cleaving itself from the main chain and consequently releasing the two halves of the product. No inhibitors are known.
{\displaystyle {\begin{array}{l}{}\\{\ce {^{235}_{92}U->[\alpha ][7.04\times 10^{8}\ {\ce {y}}]{^{231}_{90}Th}->[\beta ^{-}][25.52\ {\ce {h}}]{^{231}_{91}Pa}->[\alpha ][3.27\times 10^{4}\ {\ce {y}}]{^{227}_{89}Ac}}}{\begin{Bmatrix}{\ce {->[98.62\%\beta ^{-}][21.772\ {\ce {y}}]{^{227}_{90}Th}->[\alpha ][18.693\ {\ce {d}}]}}\\{\ce {->[1.38\%\alpha ][21.772\ {\ce {y}}]{^{223}_{87}Fr}->[\beta ^{-}][22.00\ {\ce {min}}]}}\end{Bmatrix}}{\ce {^{223}_{88}Ra->[\alpha ][11.435\ {\ce {d}}]{^{219}_{86}Rn}}}\\{\ce {^{219}_{86}Rn->[\alpha ][3.96\ {\ce {s}}]{^{215}_{84}Po}->[\alpha ][1.781\ {\ce {ms}}]{^{211}_{82}Pb}->[\beta ^{-}][36.16\ {\ce {min}}]{^{211}_{83}Bi}}}{\begin{Bmatrix}{\ce {->[99.724\%\alpha ][2.14\ {\ce {min}}]{^{207}_{81}Tl}->[\beta ^{-}][4.77\ {\ce {min}}]}}\\{\ce {->[0.276\%\beta ^{-}][2.14\ {\ce {min}}]{^{211}_{84}Po}->[\alpha ][0.516\ {\ce {s}}]}}\end{Bmatrix}}{\ce {^{207}_{82}Pb}}\end{array}}}
=== Variations === Novolog Mix 70/30 is a product which contains 30% insulin aspart and 70% insulin aspart protamine. The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection. The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day. Novolog Mix is marketed to be used with the Novo Nordisk Flexpen. The onset of action is less than 30 minutes, the peak action is reached in 1–4 hours, and the duration is less than 24 hours. NovoLog Mix is marketed in some countries as NovoMix 30. NovoRapid is produced in Saccharomyces cerevisiae by recombinant DNA technology. A faster acting version of aspart insulin, known as fast-aspart (Fiasp) insulin, is associated with more efficient control of post-prandial rise in blood glucose, without increasing the risks of hypoglycemia and glycemic variability.
== Statements by Combatants' Presidents and Prime ministers == On 7 August, state-controlled Rossiya TV aired Abkhaz separatist leader Sergei Bagapsh, who said at a meeting of the Abkhaz National Security Council: "I have spoken to the president of South Ossetia. It has more or less stabilized now. A battalion from the North Caucasus District has entered the area." The phone conversation between Bagapsh and Kokoity had taken place on late 6 August. By the evening of 7 August, Bagapsh had ordered the Abkhaz armed forces to raise combat readiness. Pro-Georgian president of South Ossetia Dmitry Sanakoyev told Russian journalist Dmitry Steshin by 8 August 2008 that neither he nor the Georgian government needed the war and cited multi-billion Georgian investment into the development of South Ossetia as a proof that Georgia was not preparing the war. Prime Minister Lado Gurgenidze said on 8 August that South Ossetian separatists launched a deliberate attack on the Georgian civilians after Saakashvili's announcement of ceasefire and that 100-vehicle armed convoy had entered through the Roki Tunnel from Russia before the midnight. Gurgenidze said that the Georgian government had notified the command of the Russian peacekeepers that Georgia was forced to respond to the attack. On 11 August 2008, Georgian president Mikheil Saakashvili wrote that the war was provoked by the Kremlin and while Georgia was showing restraint, Russia escalated the conflict in South Ossetia.
=== Validation === Validation is intended to ensure a product, service, or system (or portion thereof, or set thereof) results in a product, service, or system (or portion thereof, or set thereof) that meets the operational needs of the user. For a new development flow or verification flow, validation procedures may involve modeling either flow and using simulations to predict faults or gaps that might lead to invalid or incomplete verification or development of a product, service, or system (or portion thereof, or set thereof). A set of validation requirements (as defined by the user), specifications, and regulations may then be used as a basis for qualifying a development flow or verification flow for a product, service, or system (or portion thereof, or set thereof). Additional validation procedures also include those that are designed specifically to ensure that modifications made to an existing qualified development flow or verification flow will have the effect of producing a product, service, or system (or portion thereof, or set thereof) that meets the initial design requirements, specifications, and regulations; these validations help to keep the flow qualified. It is a process of establishing evidence that provides a high degree of assurance that a product, service, or system accomplishes its intended requirements. This often involves acceptance of fitness for purpose with end users and other product stakeholders. This is often an external process.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.